Hawaii Attorney General Weighs in on Net Neutrality
The FCC's decision is receiving a lot of backlash after repealing the net neutrality regulations. Doug Chin, Attorney General of Hawaii, joined us to share why he and 22 other state attorney generals filed a lawsuit to block the move.
Chin weighs in on what he thinks the Trump administration is ignoring with the repeal of net neutrality. The argument from Hawaii is that the rollback is “arbitrary and capricious” and goes against longstanding policy of the FCC. He says the big issue for Hawaii is they depend on internet for information since they are geographically isolated. In terms of free flow of information, he doesn’t believe it reflects the American way.
The attorney general also discusses the impact of marijuana regulations. He says the big issue is that most banks are not willing to accept money because of federal regulations preventing them from taking on the risk. This results in a cash-only grey market that makes the industry difficult to regulate, says Chin.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.
